Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation All Wales Medicines Strategy Group (AWMSG). Abacavir 600mg/lamivudine 300mg (Kivexa®) in antiretroviral combination therapy for the treatment of Human Immunodeficiency Virus infection in adults and adolescents from 12 years of age. Penarth: All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG). AWMSG Secretariat Assessment Report Advice No. 2008. 2008 Authors' conclusions Fixed dose abacavir and lamivudine (Kivexa®) is recommended as an option for use within NHS Wales in antiretroviral combination therapy for the treatment of Human Immunodeficiency Virus (HIV-1) infection in adults and adolescents from 12 years of age.
Use should be in accordance with the British HIV Association (BHIVA) guidance.
Fixed dose abacavir and lamivudine (Kivexa®) is not suitable for shared care within NHS Wales. Indexing Status Subject indexing assigned by CRD MeSH Adolescent; Adult; Anti-HIV Agentss; Dideoxynucleosides; HIV-1; Lamivudine Language Published English Country of organisation Wales English summary An English language summary is available. Address for correspondence All Wales Therapeutics and Toxicology Centre, Academic Centre, University Hospital Llandough, Penlan Road,
Penarth, Vale of Glamorgan CF64 2XX
Email: AWTTC@wales.nhs.uk AccessionNumber 32012000425 Date abstract record published 08/08/2012 |